Neoadjuvant Chemotherapy With Gemcitabine/Cisplatin/S‐1 for Resectable Biliary Tract Cancer With <scp>FDG</scp> ‐ <scp>PET</scp> ‐Positive Lymph Node Metastasis ( <scp>KHBO1201</scp> ): A Multicenter Phase <scp>II</scp> Trial
Neoadjuvant GCS chemotherapy is safe, feasible, and potentially effective for resectable BTC with FDG-PET-positive lymph nodes. A randomized phase III trial (JCOG1920) is underway to compare neoadjuvant GCS chemotherapy with upfront surgery (jRCTs031200388).
Authors
- Shogo Kobayashi (ORCID: https://orcid.org/0000-0002-8828-1067)
- Satoshi Ogiso (ORCID: https://orcid.org/0000-0002-9577-330X)
- Hiroshi Wada (ORCID: https://orcid.org/0000-0001-8862-7833)
- Tatsuya Ioka (ORCID: https://orcid.org/0000-0002-0197-1832)
- Etsuro Hatano (ORCID: https://orcid.org/0000-0003-3407-1918)
- Hidetoshi Eguchi (ORCID: https://orcid.org/0000-0002-2318-1129)
- Satoru Seo (ORCID: https://orcid.org/0000-0001-9539-8098)
- Hiroaki Nagano (ORCID: https://orcid.org/0000-0002-7074-3315)
- Masashi Kanai
- Tatsuya Higashi
Institutions
- Kansai Medical University (JP)
- Yamaguchi University (JP)
- Kyoto University (JP)
- Kochi Medical School Hospital (JP)
- National Institutes for Quantum Science and Technology (JP)
- Yamaguchi University Hospital (JP)
- Kyoto University Hospital (JP)
- Osaka International Cancer Institute (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Journal of Hepato-Biliary-Pancreatic Sciences
- Published
- 2025-11-16
- DOI
- https://doi.org/10.1002/jhbp.70030
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00